Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Receivables: 2020-2025

Historic Change in Receivables for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to $14.3 million.

  • Tarsus Pharmaceuticals' Change in Receivables rose 3961.08% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.5 million, marking a year-over-year increase of 82.63%. This contributed to the annual value of $30.1 million for FY2024, which is 81.33% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Change in Receivables is $14.3 million, which was up 449.12% from -$4.1 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Change in Receivables peaked at $25.0 million during Q1 2021, and registered a low of -$19.9 million during Q3 2021.
  • Moreover, its 3-year median value for Change in Receivables was $8.7 million (2023), whereas its average is $6.6 million.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' Change in Receivables in the last 5 years was 625,100.00% (2021), contrasted with its biggest fall of 16,566.67% (2021).
  • Over the past 5 years, Tarsus Pharmaceuticals' Change in Receivables (Quarterly) stood at -$46,000 in 2021, then plummeted by 795.65% to -$412,000 in 2022, then surged by 2,832.77% to $11.3 million in 2023, then spiked by 56.33% to $17.6 million in 2024, then spiked by 3,961.08% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q3 2025, -$4.1 million for Q2 2025, and $15.7 million during Q1 2025.